Attached files
file | filename |
---|---|
8-K - FORM 8-K - Encompass Health Corp | form8k-2009q4.htm |
EX-99.2 - EXHIBIT 99.2 - Encompass Health Corp | exhibit99-2.htm |
Exhibit
99.1
Media Contact | February 22, 2010 | |
Andy Brimmer, 205-410-2777 | For Immediate Release | |
Helen Todd, 205-969-5608 | ||
helen.todd@healthsouth.com |
Investor Relations
Contact
Mary Ann
Arico, 205-969-6175
maryann.arico@healthsouth.com
HealthSouth
Reports Strong Results for Fourth Quarter and Full Year 2009
Continued
Debt Reductions, Discharge Growth, and Effective Expense Management
2010
Guidance Reflects Continued Growth
BIRMINGHAM,
Ala. – HealthSouth Corporation (NYSE: HLS), the nation’s largest provider of
inpatient rehabilitative healthcare services, today reported its results of
operations for the fourth quarter and year ended December 31, 2009.
“The
fourth quarter was a strong conclusion to an excellent year for HealthSouth,”
said Jay Grinney, President and Chief Executive Officer of HealthSouth. “The
Company continued to execute its business plan and performed well across all key
metrics: we discharged 4.6% more patients; provided this care on a
cost-effective basis; and strengthened our balance sheet repaying approximately
$34 million of debt. For the year, we discharged 5.4% more patients and reduced
debt by approximately $151 million through the continued generation of strong
cash flows. We believe these solid results provide the necessary momentum for
another successful year in 2010.”
Fourth
Quarter Results
·
|
Consolidated
net operating revenues were $486.2 million for the fourth quarter of 2009
compared to $460.8 million for the fourth quarter of 2008, or an increase
of 5.5%. This increase was driven primarily by a 4.6% quarter-over-quarter
increase in patient discharges. Discharges increased by 4.2% quarter over
quarter on a same store basis.
|
·
|
Reported
net income per diluted share for the fourth quarter of 2009 was $0.35 per
share compared to $1.81 per diluted share for the fourth quarter of 2008.
The Company’s results for the fourth quarter of 2008 included a $121.3
million, or $1.20 per diluted share, gain associated with the UBS
Settlement and an income tax benefit of $48.4 million, or $0.48 per
diluted share, primarily related to an additional income tax refund for
tax years 1995 through 1999.
|
·
|
Adjusted
net income from continuing operations (see attached supplemental
information) for the fourth quarter of 2009, which included a $15.6
million, or $0.14 per diluted share, loss on early extinguishment of debt
related to the Company’s previously reported debt refinancing transaction
in the quarter, was $0.22 per diluted share compared to $0.24 per diluted
share for the fourth quarter of 2008. Excluding the loss on early
extinguishment of debt, the Company experienced quarter-over-quarter
growth due primarily to increased revenues, lower interest expense, and
effective expense management.
|
·
|
Adjusted
Consolidated EBITDA (see attached supplemental information) for the fourth
quarter of 2009 was $94.7 million compared to $87.5 million in the fourth
quarter of 2008, or an increase of 8.2%. This increase resulted from
increased revenues, as discussed above, and effective expense
management.
|
Exhibit
99.1
Full Year Results
·
|
Consolidated
net operating revenues were $1,911.1 million for the year ended December
31, 2009 compared to $1,829.5 million for the year ended December 31,
2008, or an increase of 4.5%. This increase was primarily attributable to
a 5.4% year-over-year increase in patient discharges. Discharges increased
by 4.8% year over year on a same store
basis.
|
·
|
Reported
net income per diluted share for the year ended December 31, 2009 was
$0.77 per share compared to $2.62 per diluted share for the year ended
December 31, 2008. The Company’s results for the year ended December 31, 2008 included
$188.5 million, or $1.96 per diluted share, of gains associated with
government, class action, and related settlements, including the $121.3
million gain associated with the UBS Settlement mentioned
above.
|
·
|
Adjusted
income from continuing operations was $1.45 per diluted share for the year
ended December 31, 2009 compared to $0.76 per diluted share for the
year ended December 31, 2008. The year-over-year growth was due primarily
to increased revenues, lower interest expense, and effective expense
management.
|
·
|
Adjusted
Consolidated EBITDA for the year ended December 31, 2009 was $383.0
million compared to $341.2 million for the year ended December 31, 2008,
or an increase of 12.3%. This increase was driven by increased revenues,
as discussed above, and effective expense
management.
|
As of December 31, 2009, total debt
outstanding approximated $1.7 billion, with no amounts drawn on the Company’s
$400 million revolving credit facility. During 2009, the Company reduced its
total debt outstanding by approximately $151 million and increased its cash and
cash equivalents by approximately $49 million. Cash flows provided by operating
activities were $406.1 million for 2009 compared to $227.2 million for 2008.
Cash flows provided by operating activities in 2009 included $73.8 million in
net cash proceeds related to the Company’s settlement with UBS and the receipt
of $63.7 million in income tax refunds associated with amended tax returns from
previous periods.
“Our
previously reported refinancing transaction, in combination with the previously
announced amendment to our credit agreement and our strong cash flow generation
in 2009, resulted in a stronger balance sheet that gives us greater flexibility
going forward,” said Ed Fay, Senior Vice President – Finance and Treasurer of
HealthSouth. “HealthSouth made significant progress on its deleveraging goal in
2009 through both debt reduction and Adjusted Consolidated EBITDA growth.
Looking ahead, our strong cash flows will continue to support further debt
reduction and new expansion opportunities for the Company.”
Due to
the Company’s debt reduction efforts and its higher Adjusted Consolidated EBITDA
(see attached supplemental information), the Company’s leverage ratio was 4.3x
as of December 31, 2009 compared to 5.3x as of December 31, 2008. The Company
remains confident it can achieve its leverage ratio goal of 3.5x to 4.0x by the
end of 2011.
2010
Guidance
Adjusted
income from continuing operations for 2010 is expected to be in the range of
$1.60 to $1.70 per diluted share, compared to $1.45 per share in 2009. Adjusted
income from continuing operations excludes any gain or loss associated with the
fair value adjustments to the Company’s interest rate swaps that are not
designated as hedges, certain professional fees (related primarily to the
Company’s derivative litigation), and other non-recurring items.
Adjusted
Consolidated EBITDA for 2010 is expected to be in the range of $397 million to
$407 million, compared to $383 million for 2009. The Company’s credit agreement
allows unusual noncash items or nonrecurring charges to be added to net income
to arrive at Adjusted Consolidated EBITDA.
See the
attached supplemental information, as well as the Current Report on Form 8-K
furnished with this press release on February 22, 2010, for additional
information related to our use and the definitions of adjusted income from
continuing operations and Adjusted Consolidated EBITDA.
2
Exhibit
99.1
Earnings
Conference Call and Webcast
The
Company will host an investor conference call at 9:00 a.m. Eastern Time on
Tuesday, February 23, 2010 to discuss its results for the fourth quarter of
2009. For reference during the call, the Company will post certain supplemental
slides at http://investor.healthsouth.com.
The
conference call may be accessed by dialing 866-406-5369 and giving the pass code
48454905. International callers should dial 973-582-2847 and give the same pass
code. Please call approximately ten minutes before the start of the call to
ensure you are connected. The conference call will
also be webcast live and will be available at http://investor.healthsouth.com by
clicking on an available link.
A replay
of the conference call will be available, beginning approximately two hours
after the completion of the conference call, from February 23 until March 9,
2010. To access the replay, please dial 800-642-1687. International callers
should dial 706-645-9291. The webcast will also be archived for replay purposes
after the live broadcast at http://investor.healthsouth.com.
About
HealthSouth
HealthSouth
is the nation’s largest provider of inpatient rehabilitative healthcare
services. Operating in 26 states across the country and in Puerto Rico,
HealthSouth serves patients through its network of inpatient rehabilitation
hospitals, long-term acute care hospitals, outpatient rehabilitation satellites,
and home health agencies. HealthSouth strives to be the nation’s preeminent
provider of inpatient rehabilitative healthcare services and can be found on the
Web at www.healthsouth.com.
Other
Information
The
Company’s leverage ratio that is referenced in this release and elsewhere from
time to time is defined in the Company’s credit agreement as the ratio of
consolidated total debt to Adjusted Consolidated EBITDA for the trailing four
quarters. Reconciliations of net income to Adjusted Consolidated EBITDA can be
found in the following schedules.
On
January 1, 2009, we reclassified our noncontrolling interests (formerly known as
“minority interests”) as a component of equity and now report net income and
comprehensive income attributable to our noncontrolling interests separately
from net income and comprehensive income attributable to HealthSouth. Due to the
adoption of this accounting guidance, all prior period amounts presented in the
attached financial information are labeled “as adjusted.”
The
information in this press release is summarized and should be read in
conjunction with the Company’s Annual Report on Form 10-K for the year ended
December 31, 2009 (the “2009 Form 10-K”), when filed, as well as the Company’s
Current Report on Form 8-K filed on February 22, 2010. In addition, the Company
will post supplemental slides today on its website at
http://investor.healthsouth.com for reference during its February 23, 2010
earnings call.
The
Company expects to file its 2009 Form 10-K this week. When filed, the report can
be found on the Company’s website at http://investor.healthsouth.com and the
SEC’s website at www.sec.gov.
3
Exhibit
99.1
HealthSouth
Corporation and Subsidiaries
Consolidated
Statements of Operations
(Unaudited)
Three
Months Ended
|
Year
Ended
|
|||||||||||||||
December
31,
|
December
31,
|
|||||||||||||||
2009
|
2008
|
2009
|
2008
|
|||||||||||||
(As
Adjusted)
|
(As
Adjusted)
|
|||||||||||||||
(In
Millions, Except Per Share Data)
|
||||||||||||||||
Net
operating revenues
|
$ | 486.2 | $ | 460.8 | $ | 1,911.1 | $ | 1,829.5 | ||||||||
Operating
expenses:
|
||||||||||||||||
Salaries
and benefits
|
243.7 | 232.1 | 948.8 | 928.2 | ||||||||||||
Other
operating expenses
|
70.8 | 65.6 | 271.4 | 264.9 | ||||||||||||
General
and administrative expenses
|
28.1 | 26.7 | 104.5 | 105.5 | ||||||||||||
Supplies
|
28.8 | 27.6 | 112.4 | 108.2 | ||||||||||||
Depreciation
and amortization
|
18.1 | 17.7 | 70.9 | 82.4 | ||||||||||||
Impairment
of long-lived assets
|
- | - | - | 0.6 | ||||||||||||
Gain
on UBS Settlement
|
- | (121.3 | ) | - | (121.3 | ) | ||||||||||
Occupancy
costs
|
11.8 | 12.0 | 47.6 | 48.8 | ||||||||||||
Provision
for doubtful accounts
|
7.8 | 6.9 | 33.1 | 27.0 | ||||||||||||
Loss
on disposal of assets
|
0.5 | 1.4 | 3.5 | 2.0 | ||||||||||||
Government,
class action, and related settlements expense
|
(4.6 | ) | (39.3 | ) | 36.7 | (67.2 | ) | |||||||||
Professional
fees—accounting, tax, and legal
|
3.8 | 31.5 | 8.8 | 44.4 | ||||||||||||
Total
operating expenses
|
408.8 | 260.9 | 1,637.7 | 1,423.5 | ||||||||||||
Loss
on early extinguishment of debt
|
15.6 | 0.1 | 12.5 | 5.9 | ||||||||||||
Interest
expense and amortization of debt discounts and fees
|
30.8 | 28.4 | 125.8 | 159.5 | ||||||||||||
Other
(income) expense
|
(2.0 | ) | 2.0 | (3.4 | ) | - | ||||||||||
Loss
on interest rate swaps
|
2.9 | 39.6 | 19.6 | 55.7 | ||||||||||||
Equity
in net income of nonconsolidated affiliates
|
(1.8 | ) | (2.8 | ) | (4.6 | ) | (10.6 | ) | ||||||||
Income
from continuing operations before income tax benefit
|
31.9 | 132.6 | 123.5 | 195.5 | ||||||||||||
Provision
for income tax benefit
|
(2.4 | ) | (48.4 | ) | (3.2 | ) | (70.1 | ) | ||||||||
Income
from continuing operations
|
34.3 | 181.0 | 126.7 | 265.6 | ||||||||||||
Income
from discontinued operations, net of tax
|
12.6 | 9.2 | 2.1 | 16.2 | ||||||||||||
Net
income
|
46.9 | 190.2 | 128.8 | 281.8 | ||||||||||||
Less:
Net income attributable to noncontrolling interests
|
(8.3 | ) | (8.3 | ) | (34.0 | ) | (29.4 | ) | ||||||||
Net
income attributable to HealthSouth
|
38.6 | 181.9 | 94.8 | 252.4 | ||||||||||||
Less:
Convertible perpetual preferred stock dividends
|
(6.5 | ) | (6.5 | ) | (26.0 | ) | (26.0 | ) | ||||||||
Net
income attributable to HealthSouth common shareholders
|
$ | 32.1 | $ | 175.4 | $ | 68.8 | $ | 226.4 | ||||||||
Weighted
average common shares outstanding:
|
||||||||||||||||
Basic
|
92.6 | 87.4 | 88.8 | 83.0 | ||||||||||||
Diluted
|
107.8 | 100.7 | 103.3 | 96.4 | ||||||||||||
Earnings
per common share:
|
||||||||||||||||
Basic:
|
||||||||||||||||
Income
from continuing operations attributable to HealthSouth common
shareholders
|
$ | 0.22 | $ | 1.91 | $ | 0.76 | $ | 2.53 | ||||||||
Income
from discontinued operations, net of tax, attributable to
HealthSouth common shareholders
|
0.13 | 0.10 | 0.01 | 0.20 | ||||||||||||
Net
income per share attributable to HealthSouth common
shareholders
|
$ | 0.35 | $ | 2.01 | $ | 0.77 | $ | 2.73 | ||||||||
Diluted:
|
||||||||||||||||
Income
from continuing operations attributable to HealthSouth common
shareholders
|
$ | 0.22 | $ | 1.72 | $ | 0.76 | $ | 2.45 | ||||||||
Income
from discontinued operations, net of tax, attributable to
HealthSouth common shareholders
|
0.13 | 0.09 | 0.01 | 0.17 | ||||||||||||
Net
income per share attributable to HealthSouth common
shareholders
|
$ | 0.35 | $ | 1.81 | $ | 0.77 | $ | 2.62 | ||||||||
Amounts
attributable to HealthSouth:
|
||||||||||||||||
Income
from continuing operations
|
$ | 26.1 | $ | 172.9 | $ | 93.3 | $ | 235.8 | ||||||||
Income
from discontinued operations, net of tax
|
12.5 | 9.0 | 1.5 | 16.6 | ||||||||||||
Net
income attributable to HealthSouth
|
$ | 38.6 | $ | 181.9 | $ | 94.8 | $ | 252.4 |
4
Exhibit
99.1
HealthSouth
Corporation and Subsidiaries
Consolidated
Balance Sheets
(Unaudited)
As
of December 31,
|
||||||||
2009
|
2008
|
|||||||
(As
Adjusted)
|
||||||||
(In
Millions, Except Share Data)
|
||||||||
Assets
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 80.9 | $ | 32.1 | ||||
Restricted
cash
|
67.8 | 154.0 | ||||||
Restricted
marketable securities
|
2.7 | 20.3 | ||||||
Accounts
receivable, net of allowance for doubtful accounts of $33.1
in 2009; $30.9 in 2008
|
219.7 | 234.9 | ||||||
Prepaid
expenses and other current assets
|
54.9 | 58.6 | ||||||
Insurance
recoveries receivable
|
- | 182.8 | ||||||
Total
current assets
|
426.0 | 682.7 | ||||||
Property
and equipment, net
|
664.8 | 662.1 | ||||||
Goodwill
|
416.4 | 414.7 | ||||||
Intangible
assets, net
|
37.4 | 42.4 | ||||||
Investments
in and advances to nonconsolidated affiliates
|
29.3 | 36.7 | ||||||
Income
tax refund receivable
|
10.0 | 55.9 | ||||||
Other
long-term assets
|
97.6 | 103.7 | ||||||
Total
assets
|
$ | 1,681.5 | $ | 1,998.2 | ||||
Liabilities
and Shareholders’ Deficit
|
||||||||
Current
liabilities
|
||||||||
Current
portion of long-term debt
|
$ | 21.5 | $ | 23.6 | ||||
Accounts
payable
|
50.2 | 45.5 | ||||||
Accrued
payroll
|
77.9 | 89.8 | ||||||
Refunds
due patients and other third-party payors
|
53.0 | 48.8 | ||||||
Other
current liabilities
|
182.0 | 270.0 | ||||||
Government,
class action, and related settlements
|
6.6 | 268.5 | ||||||
Total
current liabilities
|
391.2 | 746.2 | ||||||
Long-term
debt, net of current portion
|
1,641.0 | 1,789.6 | ||||||
Self-insured
risks
|
100.0 | 108.6 | ||||||
Other
long-term liabilities
|
59.5 | 53.6 | ||||||
2,191.7 | 2,698.0 | |||||||
Commitments
and contingencies
|
||||||||
Convertible
perpetual preferred stock
|
387.4 | 387.4 | ||||||
Shareholders’
deficit:
|
||||||||
HealthSouth
shareholders' deficit
|
(974.0 | ) | (1,169.4 | ) | ||||
Noncontrolling
interests
|
76.4 | 82.2 | ||||||
Total
shareholders' deficit
|
(897.6 | ) | (1,087.2 | ) | ||||
Total
liabilities and shareholders’ deficit
|
$ | 1,681.5 | $ | 1,998.2 |
5
Exhibit
99.1
HealthSouth
Corporation
Consolidated
Statements of Cash Flows
(Unaudited)
For
the Year Ended
|
||||||||
December
31,
|
||||||||
2009
|
2008
|
|||||||
(As
Adjusted)
|
||||||||
(In
Millions)
|
||||||||
Cash
flows from operating activities:
|
||||||||
Net
income
|
$ | 128.8 | $ | 281.8 | ||||
Income
from discontinued operations
|
(2.1 | ) | (16.2 | ) | ||||
Adjustments
to reconcile net income to net cash provided by operating
activities—
|
||||||||
Provision
for doubtful accounts
|
33.1 | 27.0 | ||||||
Provision
for government, class action, and related settlements
|
36.7 | (90.6 | ) | |||||
UBS
Settlement proceeds, gross
|
100.0 | (97.9 | ) | |||||
Depreciation
and amortization
|
70.9 | 82.4 | ||||||
Amortization
of debt issue costs, debt discounts, and fees
|
6.6 | 6.5 | ||||||
Impairment
of long-lived assets
|
- | 0.6 | ||||||
Realized
(gain) loss on sale of investments
|
(0.8 | ) | 1.4 | |||||
Loss
on disposal of assets
|
3.5 | 2.0 | ||||||
Loss
on early extinguishment of debt
|
12.5 | 5.9 | ||||||
Loss
on interest rate swaps
|
19.6 | 55.7 | ||||||
Equity
in net income of nonconsolidated affiliates
|
(4.6 | ) | (10.6 | ) | ||||
Distributions
from nonconsolidated affiliates
|
8.6 | 10.9 | ||||||
Stock-based
compensation
|
13.4 | 11.7 | ||||||
Deferred
tax provision
|
4.1 | 3.7 | ||||||
Other
|
1.3 | 2.0 | ||||||
(Increase)
decrease in assets—
|
||||||||
Accounts
receivable
|
(17.8 | ) | (45.0 | ) | ||||
Prepaid
expenses and other assets
|
3.7 | 7.5 | ||||||
Income
tax refund receivable
|
45.9 | (3.4 | ) | |||||
Increase
(decrease) in liabilities—
|
||||||||
Accounts
payable
|
4.8 | (4.2 | ) | |||||
Accrued
payroll
|
(12.4 | ) | 9.0 | |||||
Accrued
fees and expenses for derivative plaintiffs' attorneys in UBS
Settlement
|
(26.2 | ) | - | |||||
Other
liabilities
|
(1.4 | ) | 2.9 | |||||
Refunds
due patients and other third-party payors
|
4.2 | (2.5 | ) | |||||
Self-insured
risks
|
(1.6 | ) | (17.4 | ) | ||||
Government,
class action, and related settlements
|
(11.2 | ) | (7.4 | ) | ||||
Net
cash (used in) provided by operating activities of discontinued
operations
|
(13.5 | ) | 11.4 | |||||
Total
adjustments
|
279.4 | (38.4 | ) | |||||
Net
cash provided by operating activities
|
406.1 | 227.2 |
(Continued)
6
Exhibit
99.1
HealthSouth
Corporation
Consolidated
Statements of Cash Flows (Continued)
(Unaudited)
For
The Year Ended
|
||||||||
December
31,
|
||||||||
2009
|
2008
|
|||||||
(As
Adjusted)
|
||||||||
(In
Millions)
|
||||||||
Cash
flows from investing activities:
|
||||||||
Capital
expenditures
|
(72.2 | ) | (55.7 | ) | ||||
Acquisition
of business, net of assets acquired
|
- | (14.6 | ) | |||||
Acquisition
of intangible assets
|
(0.4 | ) | (18.2 | ) | ||||
Proceeds
from disposal of assets
|
3.9 | 53.9 | ||||||
Proceeds
from sale of restricted marketable securities
|
5.0 | 8.1 | ||||||
Proceeds
from sale of investments
|
0.6 | 4.3 | ||||||
Purchase
of restricted marketable securities
|
(3.8 | ) | (4.8 | ) | ||||
Net
change in restricted cash
|
(11.7 | ) | 7.5 | |||||
Net
settlements on interest rate swaps
|
(42.2 | ) | (20.7 | ) | ||||
Net
investment in interest rate swap
|
(6.4 | ) | - | |||||
Other
|
(5.3 | ) | 0.6 | |||||
Net
cash used in investing activities of discontinued
operations
|
(0.5 | ) | (0.4 | ) | ||||
Net
cash used in investing activities
|
(133.0 | ) | (40.0 | ) | ||||
Cash
flows from financing activities:
|
||||||||
Checks
in excess of bank balance
|
- | (11.4 | ) | |||||
Principal
borrowings on notes
|
15.5 | - | ||||||
Proceeds
from bond issuance
|
290.0 | - | ||||||
Principal
payments on debt, including pre-payments
|
(409.2 | ) | (204.8 | ) | ||||
Borrowings
on revolving credit facility
|
10.0 | 128.0 | ||||||
Payments
on revolving credit facility
|
(50.0 | ) | (163.0 | ) | ||||
Principal
payments under capital lease obligations
|
(13.4 | ) | (12.4 | ) | ||||
Issuance
of common stock
|
- | 150.2 | ||||||
Dividends
paid on convertible perpetual preferred stock
|
(26.0 | ) | (26.0 | ) | ||||
Debt
amendment and issuance costs
|
(10.6 | ) | - | |||||
Distributions
paid to noncontrolling interests of consolidated
affiliates
|
(32.7 | ) | (33.4 | ) | ||||
Other
|
0.8 | 0.6 | ||||||
Net
cash provided by (used in) financing activities of discontinued
operations
|
1.3 | (3.8 | ) | |||||
Net
cash used in financing activities
|
(224.3 | ) | (176.0 | ) | ||||
Effect
of exchange rate changes on cash and cash equivalents
|
- | 0.8 | ||||||
Increase
in cash and cash equivalents
|
48.8 | 12.0 | ||||||
Cash
and cash equivalents at beginning of year
|
32.1 | 19.8 | ||||||
Cash
and cash equivalents of divisions and facilities held for
sale at beginning of
year
|
0.1 | 0.4 | ||||||
Less:
Cash and cash equivalents of divisions and facilities held for sale at end of year
|
(0.1 | ) | (0.1 | ) | ||||
Cash
and cash equivalents at end of year
|
$ | 80.9 | $ | 32.1 |
7
Exhibit
99.1
HealthSouth
Corporation and Subsidiaries
Supplemental
Non-GAAP Disclosures
Reconciliation
of Net Income to Adjusted Income from Continuing Operations
and
Adjusted Consolidated EBITDA
(1) (4)
Three
Months Ended December 31,
|
||||||||||||||||
2009
|
Per
Share
(2)
|
2008
|
Per
Share(2)
|
|||||||||||||
(As
Adjusted)
|
||||||||||||||||
(In
Millions, Except per Share Data)
|
||||||||||||||||
Net
income
|
$ | 46.9 | $ | 0.51 | $ | 190.2 | $ | 2.18 | ||||||||
Income
from discontinued operations, net of tax, attributable to
HealthSouth
|
(12.5 | ) | (0.14 | ) | (9.0 | ) | (0.10 | ) | ||||||||
Net
income attributable to noncontrolling interests
|
(8.3 | ) | (0.09 | ) | (8.3 | ) | (0.09 | ) | ||||||||
Income
from continuing operations attributable to
HealthSouth
|
26.1 | 0.28 | 172.9 | 1.98 | ||||||||||||
Gain
on UBS Settlement
|
- | - | (121.3 | ) | (1.39 | ) | ||||||||||
Government,
class action, and related settlements
|
(4.6 | ) | (0.05 | ) | (39.3 | ) | (0.45 | ) | ||||||||
Professional
fees – accounting, tax, and legal
|
3.8 | 0.04 | 31.5 | 0.36 | ||||||||||||
Loss
on interest rate swaps
|
2.9 | 0.03 | 39.6 | 0.45 | ||||||||||||
Interest
associated with UBS settlement (6)
|
- | - | (9.4 | ) | (0.11 | ) | ||||||||||
Adjustment
for prior period amounts in tax provision
|
(4.1 | ) | (0.04 | ) | (49.7 | ) | (0.57 | ) | ||||||||
Adjusted
income from continuing operations (1)
(4)
|
24.1 | 0.26 | 24.3 | 0.28 | ||||||||||||
Adjustment
for dilution (2)
|
(0.04 | ) | (0.04 | ) | ||||||||||||
Adjusted
income from continuing operations per diluted share (2)
(4)
|
$ | 0.22 | $ | 0.24 | ||||||||||||
Current
period amounts in tax provision
|
1.7 | 1.3 | ||||||||||||||
Interest
expense and amortization of debt discounts and fees, excluding
interest associated with UBS settlement
|
30.8 | 37.8 | ||||||||||||||
Depreciation
and amortization
|
18.1 | 17.7 | ||||||||||||||
74.7 | 81.1 | |||||||||||||||
Other
adjustments per the Company's
|
||||||||||||||||
Credit
Agreement:
|
||||||||||||||||
Impairment
charges, including investments
|
0.2 | 1.8 | ||||||||||||||
Net
noncash loss on disposal of assets
|
0.5 | 1.4 | ||||||||||||||
Loss
on early extinguishment of debt
|
15.6 | 0.1 | ||||||||||||||
Stock-based
compensation expense
|
3.4 | 3.2 | ||||||||||||||
Other
|
0.3 | (0.1 | ) | |||||||||||||
Adjusted
Consolidated EBITDA (1) (4)
(5)
|
$ | 94.7 | $ | 87.5 | ||||||||||||
Weighted
average common shares outstanding:
|
||||||||||||||||
Basic
|
92.6 | 87.4 | ||||||||||||||
Diluted
|
107.8 | 100.7 |
8
Exhibit
99.1
HealthSouth
Corporation and Subsidiaries
Supplemental
Non-GAAP Disclosures
Reconciliation
of Net Income to Adjusted Income from Continuing Operations
and
Adjusted Consolidated EBITDA
(1) (4)
Year
Ended December 31,
|
||||||||||||||||
2009
|
Per
Share
(2)
|
2008
|
Per
Share(2)
|
|||||||||||||
(As
Adjusted)
|
||||||||||||||||
(In
Millions, Except per Share Data)
|
||||||||||||||||
Net
income
|
$ | 128.8 | $ | 1.45 | $ | 281.8 | $ | 3.40 | ||||||||
Income
from discontinued operations, net of tax, attributable to
HealthSouth
|
(1.5 | ) | (0.02 | ) | (16.6 | ) | (0.20 | ) | ||||||||
Net
income attributable to noncontrolling interests
|
(34.0 | ) | (0.38 | ) | (29.4 | ) | (0.35 | ) | ||||||||
Income
from continuing operations attributable to HealthSouth
|
93.3 | 1.05 | 235.8 | 2.84 | ||||||||||||
Gain
on UBS Settlement
|
- | - | (121.3 | ) | (1.46 | ) | ||||||||||
Government,
class action, and related settlements
|
36.7 | 0.41 | (67.2 | ) | (0.81 | ) | ||||||||||
Professional
fees – accounting, tax, and legal
|
8.8 | 0.10 | 44.4 | 0.53 | ||||||||||||
Loss
on interest rate swaps
|
19.6 | 0.22 | 55.7 | 0.67 | ||||||||||||
Accelerated
depreciation of corporate campus (3)
|
- | - | 10.0 | 0.12 | ||||||||||||
Interest
associated with UBS settlement (6)
|
- | - | (9.4 | ) | (0.11 | ) | ||||||||||
Adjustment
for prior period amounts in tax provision
|
(8.8 | ) | (0.10 | ) | (75.1 | ) | (0.90 | ) | ||||||||
Adjusted
income from continuing operations (1)
(4)
|
149.6 | 1.68 | 72.9 | 0.88 | ||||||||||||
Adjustment
for dilution (2)
|
(0.23 | ) | (0.12 | ) | ||||||||||||
Adjusted
income from continuing operations per diluted share (2)
(4)
|
$ | 1.45 | $ | 0.76 | ||||||||||||
Estimated
income tax expense
|
5.6 | 5.0 | ||||||||||||||
Interest
expense and amortization of debt discounts and fees, excluding
interest associated with UBS settlement
|
125.8 | 168.9 | ||||||||||||||
Depreciation
and amortization, excluding accelerated depreciation of corporate
campus (3)
|
70.9 | 72.4 | ||||||||||||||
351.9 | 319.2 | |||||||||||||||
Other
adjustments per the Company's
|
||||||||||||||||
Credit
Agreement:
|
||||||||||||||||
Impairment
charges, including investments
|
1.4 | 2.4 | ||||||||||||||
Net
noncash loss on disposal of assets
|
3.5 | 2.0 | ||||||||||||||
Loss
on early extinguishment of debt
|
12.5 | 5.9 | ||||||||||||||
Stock-based
compensation expense
|
13.4 | 11.7 | ||||||||||||||
Other
|
0.3 | - | ||||||||||||||
Adjusted
Consolidated EBITDA (1) (4)
(5)
|
$ | 383.0 | $ | 341.2 | ||||||||||||
Weighted
average common shares outstanding:
|
||||||||||||||||
Basic
|
88.8 | 83.0 | ||||||||||||||
Diluted
|
103.3 | 96.4 |
9
Exhibit
99.1
HealthSouth
Corporation and Subsidiaries
Supplemental
Non-GAAP Disclosures
Notes
to Reconciliations
(1)
Adjusted income from continuing operations and Adjusted Consolidated EBITDA are
non-GAAP financial measures. The Company’s leverage ratio (consolidated total
debt to Adjusted Consolidated EBITDA for the trailing four quarters) is likewise
a non-GAAP financial measure. Management and some members of the investment
community utilize adjusted income from continuing operations as a financial
measure and Adjusted Consolidated EBITDA and the leverage ratio as liquidity
measures on an ongoing basis. These measures are not recognized in accordance
with GAAP and should not be viewed as an alternative to GAAP measures of
performance or liquidity. In evaluating these adjusted measures, the reader
should be aware that in the future HealthSouth may incur expenses similar to the
adjustments set forth above.
(2) Per
share amounts for each period presented are based on basic weighted average
common shares outstanding for all amounts except adjusted income from continuing
operations per diluted share, which is based on diluted weighted average common
shares outstanding. The diluted share counts contain approximately 13.1 million
shares related to the potential dilution of the Company’s convertible perpetual
preferred stock. The increase in the Company’s basic and diluted weighted
average common shares outstanding in 2009 compared to 2008 was primarily the
result of its equity offering of 8.8 million shares that was completed on June
27, 2008 and the issuance of 5.0 million shares of common stock on September 30,
2009 in full satisfaction of its obligation to do so under the Company’s
securities litigation settlement.
(3) In
the first quarter of 2008, the Company accelerated the depreciation of its
corporate campus so that the net book value of the campus equaled the estimated
net proceeds the Company expected to receive on the sale transaction’s closing
date. The year-over-year impact of this acceleration of depreciation
approximated $10 million. No similar charges happened in 2009.
(4)
Adjusted income from continuing operations per diluted share and Adjusted
Consolidated EBITDA are two components of the Company’s guidance.
(5) The
Company’s credit agreement allows unusual non-cash or non-recurring items to be
added to arrive at Adjusted Consolidated EBITDA. In addition, certain other
deductions may be required. Such amounts have not been included in the above
calculation as it would not be indicative of the Company’s Adjusted Consolidated
EBITDA for future periods.
(6)
Interest expense and amortization of debt discounts and fees in the Company’s
consolidated statements of operations for the three months and year ended
December 31, 2008 included the reversal of $9.4 million of accrued interest
related to the loan guarantee for which the Company received a release as part
of the UBS Settlement.
10
Exhibit
99.1
HealthSouth
Corporation and Subsidiaries
Forward-Looking
Statements
Statements
contained in this press release which are not historical facts are
forward-looking statements. In addition, HealthSouth, through its senior
management, may from time to time make forward-looking public statements
concerning the matters described herein. All such estimates, projections, and
forward-looking information speak only as of the date hereof, and HealthSouth
undertakes no duty to publicly update or revise such forward-looking
information, whether as a result of new information, future events, or
otherwise. Such forward-looking statements are necessarily estimates based upon
current information and involve a number of risks and uncertainties.
HealthSouth’s actual results may differ materially from the results anticipated
in these forward-looking statements as a result of a variety of factors. While
it is impossible to identify all such factors, factors which could cause actual
results to differ materially from those estimated by HealthSouth include, but
are not limited to, any adverse outcome of various lawsuits, claims, and legal
or regulatory proceedings that may be brought against the Company; significant
changes in HealthSouth’s management team; HealthSouth’s ability to continue to
operate in the ordinary course and manage its relationships with its creditors,
including its lenders, bondholders, vendors and suppliers, employees, and
customers; changes, delays in (including in connection with resolution of
Medicare payment reviews or appeals), or suspension of reimbursement for
HealthSouth’s services by governmental or private payors; changes in the
regulation of the healthcare industry at either or both of the federal and state
levels; competitive pressures in the healthcare industry and HealthSouth’s
response thereto; HealthSouth’s ability to obtain and retain favorable
arrangements with third-party payors; HealthSouth’s ability to attract and
retain nurses, therapists, and other healthcare professionals in a highly
competitive environment with often severe staffing shortages and the impact on
HealthSouth’s labor expenses from potential union activity and staffing
shortages; general conditions in the economy and capital markets; and other
factors which may be identified from time to time in HealthSouth’s SEC filings
and other public announcements, including HealthSouth’s Form 10-K for the year
ended December 31, 2009, which is expected to be filed later this
week.
11